Riassunto: Incyte presenta all'ISTH 2026 i dati di fase 1/2 su dosi multiple di VGA039 (latarcibart) ed evidenzia una sostanziale riduzione del sanguinamento nei pazienti affetti da ogni tipo di malattia di von Willebrand
Tuesday, July 14, 2026 BiopharmaWatch Research 1 min read
Key Takeaway: Incyte has announced positive results from a Phase 1/2 study of VGA039 (latarcibart), an experimental monoclonal antibody targeting protein S in patients with von Willebrand disease (VWD). The study, which included 16 patients, demonstrated a substantial reduction in bleeding episodes. These findings were presented at the ISTH 2026 conference.
Price reaction · baseline $114.23 (2026-07-13 close) · hit pre-market · clean, no other INCY news in the window
day 0 close · peak
+0.6%
Market Sentiment Analysis
POSITIVE FACTORS
Incyte presented promising Phase 1/2 data on VGA039.
Significant reduction in bleeding observed in patients.
Study involved a comprehensive safety and efficacy analysis.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+44%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
INCB013739
Phase 2 · Type 2 Diabetes
Full Press Release Details
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) oggi ha annunciato i dati completi di sicurezza ed efficacia di tutti i pazienti (n=16) arruolati nello studio multidose di fase 1/2 su VGA039 (latarcibart), un innovativo anticorpo monoclonale sperimentale mirato alla proteina S nei pazienti affetti da malattia di von Willebrand (VWD). Il testo originale del presente annuncio, redatto nella lingua di partenza, è la versione ufficiale che fa fede. Le traduzioni sono offerte unicamente per
Frequently Asked Questions
What is VGA039?
VGA039, also known as latarcibart, is an experimental monoclonal antibody targeting protein S.
What disease does VGA039 target?
VGA039 targets von Willebrand disease (VWD), a bleeding disorder.
What were the results of the Phase 1/2 study?
The study showed a substantial reduction in bleeding episodes among patients.
How many patients were involved in the study?
The study included 16 patients.
Where were the results presented?
The results were presented at the ISTH 2026 conference.